---
document_datetime: 2025-12-02 05:24:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vabysmo.html
document_name: vabysmo.html
version: success
processing_time: 0.1123535
conversion_datetime: 2025-12-27 16:25:25.81566
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vabysmo

[RSS](/en/individual-human-medicine.xml/67610)

##### Authorised

This medicine is authorised for use in the European Union

faricimab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vabysmo](#news-on)
- [More information on Vabysmo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vabysmo is a medicine used to treat adults with:

- the 'wet' form of age-related macular degeneration (AMD), a disease that affects the central part of the retina (called the macula) at the back of the eye. The wet form of AMD is caused by abnormal growth of blood vessels beneath the retina which may leak fluid and blood and cause swelling;
- impaired vision due to macular oedema (swelling) caused by diabetes;
- impaired vision due to a swelling of the macula caused by retinal vein occlusion (RVO, a blockage of the blood flow in a vein of the retina).

The macula provides central vision that is needed to see details for everyday tasks such as driving, reading and recognising faces. The diseases cause the gradual loss of the central part of a person's vision.

Vabysmo contains the active substance faricimab.

Expand section

Collapse section

## How is Vabysmo used?

Vabysmo can only be obtained with a prescription and must be given by a qualified eye doctor who is experienced in giving injections into the eye.

It is given as an injection into the vitreous humour, the jelly-like fluid inside the eye. Treatment starts with one injection every four weeks. After several doses, the doctor may adjust the interval after assessing the patient's vision. Treatment with Vabysmo should be stopped if the patient is not benefitting from it.

For more information about using Vabysmo, see the package leaflet or contact your doctor or pharmacist.

## How does Vabysmo work?

The active substance in Vabysmo, faricimab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to two proteins: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2).

In patients with wet AMD and diabetic macular oedema, these proteins stimulate the abnormal growth of blood vessels that is associated with fluid and blood leakage, which damages the macula. By attaching to VEGF-A and Ang-2, faricimab blocks the action of these proteins, thereby reducing the growth of the blood vessels and controlling the leakage, swelling and inflammation.

## What benefits of Vabysmo have been shown in studies?

**AMD**

Two main studies involving 1,329 patients with the wet form of AMD showed that Vabysmo given at up to 16-week intervals was at least as effective at improving the condition as aflibercept (another medicine for the wet form of AMD) given at 8-week intervals. After a year of treatment, the average number of letters patients could recognise on a standard eye test improved by 5.8 (first study) and 6.6 letters (second study) in patients treated with Vabysmo, and by 5.1 and 6.6 letters for those given aflibercept.

**Diabetic macular oedema**

Two main studies involving 1,891 patients with diabetic macular oedema looked at the effect of Vabysmo given either at 8-week intervals or at adjustable intervals (up to 16 weeks), and of aflibercept given at 8-week intervals.

After a year of treatment, the improvement in the number of letters patients could recognise was similar for the different treatments. In the first study, this improved by 10.7 letters for patients given Vabysmo every 8 weeks, by 11.6 letters for those given Vabysmo at variable intervals, and by 10.9 letters for those given aflibercept. In the second study, the improvements were 11.8, 10.8 and 10.3 letters, respectively. In both studies, this effect was maintained throughout a second year of treatment.

**Macular oedema caused by RVO**

Two main studies involving 1,282 patients with macular oedema caused by RVO showed that Vabysmo was at least as effective as aflibercept at improving their vision. After 24 weeks of treatment (6 doses at 4-week intervals), the average number of letters patients could recognise on a standard eye test improved by 16.9 letters in patients treated with Vabysmo, compared with 17.5 (first study) and 17.3 (second study) in patients given aflibercept. After 24 weeks of treatment, patients continued Vabysmo at 4 to 16-week intervals. In both studies, the effect of Vabysmo was maintained until week 72.

## What are the risks associated with Vabysmo?

For the full list of side effects and restrictions of Vabysmo, see the package leaflet.

The most common side effects with Vabysmo (which may affect up to 1 in 10 people) include cataract (clouding of the lens), bleeding of the conjunctiva (the membrane that lines the white of the eye and the inside of the eyelid), increased pressure within the eye, vitreous floaters (small, dark shapes moving in the field of vision), eye pain, tears of the retinal pigment epithelium (only in patients with wet AMD) and increased lacrimation (watery eyes).

The most serious side effects with Vabysmo (which may affect up to 1 in 100 people) include uveitis (inflammation of the uvea, the layer beneath the white of the eyeball), vitritis (the presence of inflammatory cells in the vitreous humour), endophthalmitis (inflammation inside the eye), retinal tear and rhegmatogenous retinal detachment (the most common type of retinal detachment). Another serious side effect is traumatic cataract which may affect less than 1 in 1,000 patients.

Vabysmo must not be used in patients who may have an infection of the eye or the area around the eye, or who have a severe inflammation within the eye.

## Why is Vabysmo authorised in the EU?

Vabysmo was shown to be as effective as the comparator aflibercept at improving the vision of patients with wet AMD and macular oedema caused by diabetes or RVO. Regarding safety, the most common side effects of Vabysmo are similar to those of other products given by intravitreal injection and are considered acceptable.

The European Medicines Agency therefore decided that Vabysmo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vabysmo?

The company that markets Vabysmo will provide an information pack to patients to help them prepare for treatment, recognise signs and symptoms of serious side effects and know when to seek urgent attention from their doctor.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vabysmo have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vabysmo are continuously monitored. Suspected side effects reported with Vabysmo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vabysmo

Vabysmo received a marketing authorisation valid throughout the EU on 15 September 2022.

Vabysmo : EPAR - Medicine Overview

Reference Number: EMEA/H/C/005642

English (EN) (144.88 KB - PDF)

**First published:** 13/10/2022

**Last updated:** 29/08/2024

[View](/en/documents/overview/vabysmo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-4)

български (BG) (165.37 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/bg/documents/overview/vabysmo-epar-medicine-overview_bg.pdf)

español (ES) (136.88 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/es/documents/overview/vabysmo-epar-medicine-overview_es.pdf)

čeština (CS) (161.98 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/cs/documents/overview/vabysmo-epar-medicine-overview_cs.pdf)

dansk (DA) (137.92 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/da/documents/overview/vabysmo-epar-medicine-overview_da.pdf)

Deutsch (DE) (141.15 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/de/documents/overview/vabysmo-epar-medicine-overview_de.pdf)

eesti keel (ET) (134.91 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/et/documents/overview/vabysmo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (167.8 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/el/documents/overview/vabysmo-epar-medicine-overview_el.pdf)

français (FR) (139.82 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/fr/documents/overview/vabysmo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (159.17 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/hr/documents/overview/vabysmo-epar-medicine-overview_hr.pdf)

italiano (IT) (136.2 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/it/documents/overview/vabysmo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (169.11 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/lv/documents/overview/vabysmo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (160.38 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/lt/documents/overview/vabysmo-epar-medicine-overview_lt.pdf)

magyar (HU) (161.11 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/hu/documents/overview/vabysmo-epar-medicine-overview_hu.pdf)

Malti (MT) (164.5 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/mt/documents/overview/vabysmo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (138.8 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/nl/documents/overview/vabysmo-epar-medicine-overview_nl.pdf)

polski (PL) (166.33 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/pl/documents/overview/vabysmo-epar-medicine-overview_pl.pdf)

português (PT) (137.63 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/pt/documents/overview/vabysmo-epar-medicine-overview_pt.pdf)

română (RO) (158.76 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/ro/documents/overview/vabysmo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (162.12 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/sk/documents/overview/vabysmo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (159.77 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/sl/documents/overview/vabysmo-epar-medicine-overview_sl.pdf)

Suomi (FI) (134.57 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/fi/documents/overview/vabysmo-epar-medicine-overview_fi.pdf)

svenska (SV) (135.23 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

29/08/2024

[View](/sv/documents/overview/vabysmo-epar-medicine-overview_sv.pdf)

Vabysmo : EPAR - Risk management plan

English (EN) (1.42 MB - PDF)

**First published:** 13/10/2022

**Last updated:** 14/07/2025

[View](/en/documents/rmp/vabysmo-epar-risk-management-plan_en.pdf)

## Product information

Vabysmo : EPAR - Product Information

English (EN) (1.47 MB - PDF)

**First published:** 13/10/2022

**Last updated:** 14/07/2025

[View](/en/documents/product-information/vabysmo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-16)

български (BG) (1.74 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/bg/documents/product-information/vabysmo-epar-product-information_bg.pdf)

español (ES) (1.4 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/es/documents/product-information/vabysmo-epar-product-information_es.pdf)

čeština (CS) (1.54 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/cs/documents/product-information/vabysmo-epar-product-information_cs.pdf)

dansk (DA) (1.3 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/da/documents/product-information/vabysmo-epar-product-information_da.pdf)

Deutsch (DE) (1.93 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/de/documents/product-information/vabysmo-epar-product-information_de.pdf)

eesti keel (ET) (1.34 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/et/documents/product-information/vabysmo-epar-product-information_et.pdf)

ελληνικά (EL) (1.43 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/el/documents/product-information/vabysmo-epar-product-information_el.pdf)

français (FR) (1.32 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/fr/documents/product-information/vabysmo-epar-product-information_fr.pdf)

hrvatski (HR) (1.49 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/hr/documents/product-information/vabysmo-epar-product-information_hr.pdf)

íslenska (IS) (1.54 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/is/documents/product-information/vabysmo-epar-product-information_is.pdf)

italiano (IT) (1.34 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/it/documents/product-information/vabysmo-epar-product-information_it.pdf)

latviešu valoda (LV) (1.36 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/lv/documents/product-information/vabysmo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.47 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/lt/documents/product-information/vabysmo-epar-product-information_lt.pdf)

magyar (HU) (1.3 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/hu/documents/product-information/vabysmo-epar-product-information_hu.pdf)

Malti (MT) (1.84 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/mt/documents/product-information/vabysmo-epar-product-information_mt.pdf)

Nederlands (NL) (1.25 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/nl/documents/product-information/vabysmo-epar-product-information_nl.pdf)

norsk (NO) (1.32 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/no/documents/product-information/vabysmo-epar-product-information_no.pdf)

polski (PL) (1.64 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/pl/documents/product-information/vabysmo-epar-product-information_pl.pdf)

português (PT) (1.51 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/pt/documents/product-information/vabysmo-epar-product-information_pt.pdf)

română (RO) (1.44 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/ro/documents/product-information/vabysmo-epar-product-information_ro.pdf)

slovenčina (SK) (1.63 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/sk/documents/product-information/vabysmo-epar-product-information_sk.pdf)

slovenščina (SL) (1.44 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/sl/documents/product-information/vabysmo-epar-product-information_sl.pdf)

Suomi (FI) (1.3 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/fi/documents/product-information/vabysmo-epar-product-information_fi.pdf)

svenska (SV) (1.38 MB - PDF)

**First published:**

13/10/2022

**Last updated:**

14/07/2025

[View](/sv/documents/product-information/vabysmo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0016 08/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vabysmo : EPAR - All Authorised Presentations

English (EN) (12.88 KB - PDF)

**First published:** 13/10/2022

**Last updated:** 05/02/2025

[View](/en/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-803)

български (BG) (37.55 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/bg/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.22 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/es/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.6 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/cs/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (16.65 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/da/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (13.37 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/de/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (13.49 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/et/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (35.46 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/el/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_el.pdf)

français (FR) (13.47 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/fr/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.52 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/hr/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (13.11 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/is/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.73 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/it/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.17 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/lv/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.04 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/lt/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.01 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/hu/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.88 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/mt/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (13.1 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/nl/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (13.6 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/no/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_no.pdf)

polski (PL) (59.78 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/pl/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_pl.pdf)

português (PT) (17.15 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/pt/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_pt.pdf)

română (RO) (37.23 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/ro/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (33.98 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/sk/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (22.35 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/sl/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (13.43 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/fi/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (18.12 KB - PDF)

**First published:**

13/10/2022

**Last updated:**

05/02/2025

[View](/sv/documents/all-authorised-presentations/vabysmo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vabysmo Active substance Faricimab International non-proprietary name (INN) or common name faricimab Therapeutic area (MeSH)

- Wet Macular Degeneration
- Macular Edema
- Diabetes Complications

Anatomical therapeutic chemical (ATC) code S01L

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Vabysmo is indicated for the treatment of adult patients with:

- neovascular (wet) age-related macular degeneration (nAMD),
- visual impairment due to diabetic macular oedema (DME),
- visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).

## Authorisation details

EMA product number EMEA/H/C/005642

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Roche Registration GmbH

Emil-Barell-Strasse 1

Opinion adopted 21/07/2022 Marketing authorisation issued 15/09/2022 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vabysmo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (168.92 KB - PDF)

**First published:** 19/07/2023

**Last updated:** 14/07/2025

[View](/en/documents/procedural-steps-after/vabysmo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vabysmo-H-C-5642-II-0005 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/333706/2024

English (EN) (12.46 MB - PDF)

**First published:** 29/08/2024

[View](/en/documents/variation-report/vabysmo-h-c-5642-ii-0005-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vabysmo (II-05)

Adopted

Reference Number: EMA/CHMP/254404/2024

English (EN) (118.83 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vabysmo-ii-05_en.pdf)

## Initial marketing authorisation documents

Vabysmo : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/687844/2022

English (EN) (14.92 MB - PDF)

**First published:** 13/10/2022

[View](/en/documents/assessment-report/vabysmo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vabysmo

Adopted

Reference Number: EMA/CHMP/644170/2022

English (EN) (127.77 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vabysmo_en.pdf)

#### News on Vabysmo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 July 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-july-2022) 22/07/2022

#### More information on Vabysmo

- [Vabysmo - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vabysmo)
- [Vabysmo - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/vabysmo-0)
- [EMEA-002817-PIP05-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002817-pip05-23)
- [Incidence of Retinal Vasculitis With or Without Retinal Vascular Occlusion Among Eyes Treated With Approved Anti-Vascular Endothelial Growth Factor Agents in Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema - post-authorisation study](https://catalogues.ema.europa.eu/study/107731)

**This page was last updated on** 14/07/2025

## Share this page

[Back to top](#main-content)